Form 4: Actuate Therapeutics Director Jason Keyes Granted 15,000 Stock Options

Actuate Therapeutics, Inc. disclosed in a recent SEC Form 4 filing that Director Jason A. Keyes was granted 15,000 stock options with an exercise price of $10.10 per share, vesting fully on the anniversary of the grant date.

Summary

• Jason A. Keyes, a Director of Actuate Therapeutics, Inc. (ACTU), was granted 15,000 stock options.
• The transaction date for the option grant was May 22, 2025.
• The exercise price for these stock options is $10.10 per share.
• The options are set to vest in full on the anniversary of the grant date, which would be May 22, 2026.
• The expiration date for these stock options is May 22, 2035.
• Following this transaction, Mr. Keyes beneficially owns 15,000 derivative securities (stock options) directly.

Sentiment

Score: 6

Explanation: The document is a routine disclosure of an insider transaction (stock option grant). While not directly indicative of financial performance, it represents a standard compensation practice that aligns director interests with shareholders, which is generally viewed neutrally to slightly positive in terms of corporate governance.

Positives

• The grant of stock options to a director aligns the director's interests with those of shareholders, incentivizing long-term company performance.
• The options have a 10-year expiration period (until May 22, 2035), providing a long-term incentive horizon.

Negatives

• The exercise price of $10.10 means the stock price must exceed this value for the options to be 'in the money' and provide a direct financial benefit to the director.

Future Outlook

This Form 4 filing primarily reports a past transaction and does not contain forward-looking statements or guidance regarding the company's future financial performance or strategic direction.

Industry Context

The grant of stock options to directors is a standard practice in the biotechnology and pharmaceutical industries, as well as across publicly traded companies, to attract and retain talent and align management incentives with shareholder value creation. Actuate Therapeutics, as a publicly traded entity, follows common corporate governance and compensation practices.

Comparison to Industry Standards

• The grant of 15,000 stock options to a director is a common form of equity compensation, comparable to practices seen in other small to mid-cap biotechnology companies.
• The 10-year expiration period for the options is standard for long-term incentive plans in the industry.
• The vesting schedule, 'vest in full on the anniversary of the grant date,' is a common cliff vesting approach for director grants, similar to those observed at companies like BioNTech SE (BNTX) or Moderna, Inc. (MRNA) for certain types of grants, though specific terms vary by company size and compensation philosophy.

Stakeholder Impact

• Shareholders: The grant of options aligns the director's financial interests with shareholder value creation, as the options gain value only if the stock price increases above the exercise price.
• Employees: This filing specifically relates to a director's compensation and does not directly impact the broader employee base, though it reflects the company's overall compensation philosophy.

Next Steps

• The options will vest in full on May 22, 2026, at which point Jason A. Keyes will be able to exercise them.

Key Dates

Keywords

Actuate Therapeutics, ACTU, SEC Form 4, Stock Options, Insider Transaction, Director Compensation, Equity Grant, Beneficial Ownership